Eli Lilly bulks up in Ireland

In anticipation of increased demand for biopharmaceuticals, Eli Lilly ($LLY) is planning a 22,000-square-meter bioprocessing plant at its Cork County site. The Dunderrow, Kinsale, location is currently home to API production for drugs to treat diabetes, schizophrenia and depression, according to the Irish Times. Lilly's presence in Dunderrow stretches back to the early 1980s, InPharm notes.

Plans call for a three-story building on the site, in proximity to a 158,000-square-meter monoclonal antibody plant completed in 2010 and expected to be online next year. The site, one of 6 Lilly bulk manufacturing locations worldwide, is the production home for potential blockbuster Alzheimer treatment solanezumab, InPharm reports.

Eli Lilly isn't the only big drugmaker expanding its presence in Ireland. In October, Sanofi ($SNY) unit Genzyme unveiled a $207 million plant expansion in Waterford, about 150 kilometers east of the Lilly site along the coast in the south of the Emerald Isle.

- here's the story
- see the InPharm report

Special Report: Eli Lilly - The 12 greenest companies in biopharma


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.